English
Published: 2009-06-08 17:30:00 CEST
PartnerTech AB.
Company Announcement
Biotage entrusts PartnerTech with greater responsibility - Instrument manufacture
Biotage entrusts PartnerTech with greater responsibility -
Instrument
manufacture 

PartnerTech and Biotage, an international company in
the field of life science
research, have long cooperated on a far-reaching
basis. Now the two companies
are expanding their collaboration through a new
agreement according to which
PartnerTech will take over most instrument
manufacture, currently located at
Biotage's plant in Charlottesville, Virginia.
Running initially through 2011,
the agreement is worth approximately SEK 40
million annually. 

“After many years of close cooperation, we know that
PartnerTech has the
experience and organization required to handle an
assignment of this magnitude,”
says Torben Jörgensen, President and CEO of
Biotage. “We are very pleased with
PartnerTech's production capacity and rapid
response time. We have also
benefited greatly from PartnerTech's product
development division, which has
made our instruments more competitive.”


Biotage has long collaborated with PartnerTech on the development and
production
of its instruments. The new agreement involves the relocation of
instrument
manufacture from the Biotage plant in Charlottesville, Virginia to
the
PartnerTech customer center in Åtvidaberg, Sweden. After the
relocation,
PartnerTech will manufacture nearly all Biotage instruments. The
product
transfer will begin immediately. Initial deliveries will be made in
June, and
the transfer is scheduled for completion in the third quarter. 
 
“We
are very happy that Biotage is entrusting more of its production to us,”
says
Rune Glavare, President and CEO of PartnerTech. “It reaffirms that
PartnerTech
has a strong offering and the kind of expertise needed to support
product
development and the manufacture of medical devices. Our industrial
structure,
global supply chain and refined manufacturing expertise ensure that
our
customers have efficient, cost-effective and flexible production.”

For
additional information, please call: 
Rune Glavare, President and CEO,
PartnerTech AB, +46 (0) 706 20 24 54
Torben Jörgensen, President and CEO,
Biotage AB, +46 (0)707-49 05 84


Biotage
As an international company in the
field of life science research, Biotage AB
has advanced technologies,
wide-ranging operations and a long-term view of the
market. The company
provides solutions, expertise and experience in medicinal
chemistry. In 2005,
Biotage acquired operations and products from Argonaut,
further strengthening
its product portfolio in medicinal chemistry. Among its
customers are the 30
biggest pharmaceutical companies and the 20 biggest biotech
companies in the
world, as well as leading academic institutions. Headquartered
in Uppsala,
Sweden, the company has subsidiaries in the United States, Japan,
the UK,
Germany and several other European countries. Biotage (www.biotage.com)
has
some 300 employees, reported sales of SEK 385.3 million in 2008 and is
listed
on the NASDAQ OMX Nordic Exchange Stockholm. 

PartnerTech
PartnerTech develops
and manufactures products under contract for leading
companies, primarily in
Defense and Maritime, Industry, Information Technology,
MedTech &
Instrumentation, CleanTech and Point of Sale Applications. With some
1,500
employees at its plants in Sweden, Norway, Finland, Poland, the UK, the
United
States and China, PartnerTech reports annual sales of approximately SEK
2.5
billion. PartnerTech AB (www.partnertech.com), the parent company,
is
headquartered in Malmö, Sweden and listed on the NASDAQ OMX Nordic
Exchange
Stockholm. www.partnertech.se

The disclosures have been sent to the
Swedish Financial Supervisory Authority
(Finansinspektionen). 
 


06082362.pdf